Board of Directors

Charles is a Principal on the biotech team at SV Health Investors, helping to form and fund companies developing transformational new medicines, with a broad focus ranging from new company creation to later-stage public and private opportunities. He serves as a Board Director at Mestag Therapeutics and Draig Therapeutics, an SV-created clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, which he incubated and launched as the deal lead. Charles is a Board Observer at Autifony Therapeutics and Pulmocide. 

Before joining SV Health Investors in 2018, he qualified as an Associate Chartered Accountant (ACA) after three years at Deloitte, with a focus on life sciences clients, including SV portfolio companies, and has an academic background in human genetics & molecular biology. Charles holds an MSci Human Genetics from University College London.